LOUISVILLE, Colo., Jan. 12 /PRNewswire/ -- RxKinetix, Inc., a specialty
pharmaceutical company developing new therapeutics focused in oncology care,
today announced that the Company has been awarded the Life Sciences Company of
the Year Award by the University of Colorado Technology Transfer Office.
RxKinetix holds license to two technologies from the University License
Equity Holdings, Inc. relating to drug delivery. The Company recently
completed a successful Phase 2 clinical trial for its lead product, RK-0202
for treatment of oral mucositis in head and neck cancer patients. "We are
honored to receive this award from the University of Colorado Technology
Transfer Office. It is a wonderful endorsement of our on-going success and
recognition of the excellent work of all the employees of RxKinetix," said
Harry Ross M. D., chairman and CEO of RxKinetix.
"RxKinetix' successful Phase 2 clinical trial for RK-0202 made it an
obvious choice for this award. It is always gratifying to see success from a
company founded on technology from the University of Colorado," said David
Allen, Associate Vice President for Technology Transfer, University of
Colorado.
RxKinetix, Inc. is a specialty pharmaceutical company developing new
therapeutics focused in oncology care. Using proven pharmaceuticals and
proprietary polymer-based drug delivery technologies, RxKinetix creates new
drugs or enhances existing drugs. The Company's strategy improves timelines
and reduces risk during clinical development. RxKinetix has a strong
intellectual property portfolio in support of its products and technologies.
More information regarding RxKinetix is available at http://www.rxkinetix.com.
SOURCE RxKinetix, Inc.
 back to top
Related links:
http://www.rxkinetix.com
CONTACT:
Joanna Money, Ph.D., Vice President,
Corporate Development of RxKinetix, Inc., +1-303-926-1900,
jmoney@rxkinetix.com
|
